Long-term tenofovir disoproxil fumarate ( TDF ) treatment for chronic hepatitis B ( CHB ) is associated with sustained viral suppression and regression of fibrosis and cirrhosis at year 5 ( 240 weeks ) and no TDF resistance through 6 years ( 288 weeks ) .